JP2017515815A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515815A5
JP2017515815A5 JP2016565473A JP2016565473A JP2017515815A5 JP 2017515815 A5 JP2017515815 A5 JP 2017515815A5 JP 2016565473 A JP2016565473 A JP 2016565473A JP 2016565473 A JP2016565473 A JP 2016565473A JP 2017515815 A5 JP2017515815 A5 JP 2017515815A5
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
acid sequence
interferon alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016565473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515815A (ja
JP6550400B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/001600 external-priority patent/WO2015181641A2/en
Publication of JP2017515815A publication Critical patent/JP2017515815A/ja
Publication of JP2017515815A5 publication Critical patent/JP2017515815A5/ja
Application granted granted Critical
Publication of JP6550400B2 publication Critical patent/JP6550400B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016565473A 2014-05-01 2015-05-01 レナリドミド及びポリペプチド構築物の組合せ、及びその使用 Active JP6550400B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461986913P 2014-05-01 2014-05-01
US61/986,913 2014-05-01
PCT/IB2015/001600 WO2015181641A2 (en) 2014-05-01 2015-05-01 Combination of lenalidomide and polypeptide construct, and uses thereof

Publications (3)

Publication Number Publication Date
JP2017515815A JP2017515815A (ja) 2017-06-15
JP2017515815A5 true JP2017515815A5 (cg-RX-API-DMAC7.html) 2018-06-14
JP6550400B2 JP6550400B2 (ja) 2019-07-24

Family

ID=54354398

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565473A Active JP6550400B2 (ja) 2014-05-01 2015-05-01 レナリドミド及びポリペプチド構築物の組合せ、及びその使用

Country Status (19)

Country Link
US (3) US9636334B2 (cg-RX-API-DMAC7.html)
EP (1) EP3137505B1 (cg-RX-API-DMAC7.html)
JP (1) JP6550400B2 (cg-RX-API-DMAC7.html)
KR (1) KR102412023B1 (cg-RX-API-DMAC7.html)
CN (1) CN106536562B (cg-RX-API-DMAC7.html)
AU (1) AU2015265624B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016025437A2 (cg-RX-API-DMAC7.html)
CA (1) CA2945902C (cg-RX-API-DMAC7.html)
CL (1) CL2016002733A1 (cg-RX-API-DMAC7.html)
EA (1) EA033359B1 (cg-RX-API-DMAC7.html)
ES (1) ES2736121T3 (cg-RX-API-DMAC7.html)
IL (1) IL248394B (cg-RX-API-DMAC7.html)
MA (1) MA39836A (cg-RX-API-DMAC7.html)
MX (1) MX375746B (cg-RX-API-DMAC7.html)
NZ (1) NZ725487A (cg-RX-API-DMAC7.html)
PE (1) PE20161392A1 (cg-RX-API-DMAC7.html)
PT (1) PT3137505T (cg-RX-API-DMAC7.html)
UA (1) UA119352C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015181641A2 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
ES3033729T3 (en) 2011-10-28 2025-08-07 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
PT3677591T (pt) 2013-04-29 2023-02-17 Teva Pharmaceuticals Australia Pty Ltd Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
PE20170908A1 (es) * 2014-10-29 2017-07-12 Teva Pharmaceuticals Australia Pty Ltd VARIANTES DE INTERFERON a2b
CA3013554A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Targeted therapeutic agents and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
US11613586B2 (en) 2016-07-15 2023-03-28 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
US11337975B2 (en) 2016-11-23 2022-05-24 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof
US11384154B2 (en) 2017-02-06 2022-07-12 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
CA3066893A1 (en) 2017-06-21 2018-12-27 Cephalon, Inc. Cation exchange chromatography wash buffer
MX2020000342A (es) 2017-07-11 2020-08-17 Compass Therapeutics Llc Anticuerpos agonistas que se unen a cd137 humano y sus usos.
BR112020002706A2 (pt) 2017-08-09 2020-08-25 Orionis Biosciences Inc. agentes de ligação a clec9a e uso dos mesmos
JP7347899B2 (ja) 2017-08-09 2023-09-20 オリオンズ バイオサイエンス インコーポレイテッド Ｃｄ８結合物質
WO2019032663A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. PD-1 AND PD-L1 BINDING AGENTS
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019140410A1 (en) 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
WO2019199133A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드의 경구용 코팅 정제 조성물
KR102286497B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 다양한 용량의 레날리도마이드의 경구용 정제 조성물
KR102286500B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
WO2019199135A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
WO2019199134A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 약제학적 조성물
RU2694672C1 (ru) * 2018-04-27 2019-07-16 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против интерферона альфа (IFN-α) человека, антигенсвязывающий фрагмент (Fab) против IFN-α человека, содержащий указанные домены
CA3108795A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. Sirp1a targeted chimeric proteins and uses thereof
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
EP3947429A4 (en) 2019-03-28 2023-05-17 Orionis Biosciences, Inc. CHIMERIC PROTEIN COMPLEXES BASED ON CLEC9A
EP3980064A1 (en) 2019-06-10 2022-04-13 Takeda Pharmaceutical Company Limited Combination therapies using cd-38 antibodies
IL293450A (en) 2019-12-03 2022-07-01 Evotec Int Gmbh Interferon-associated antigen binding proteins and uses thereof
JP2025516856A (ja) 2022-05-18 2025-05-30 武田薬品工業株式会社 抗ｃｄ３８融合タンパク質製剤
WO2023227949A1 (en) * 2022-05-27 2023-11-30 Takeda Pharmaceutical Company Limited Dosing of cd38-binding fusion protein
WO2024069240A2 (en) * 2022-09-29 2024-04-04 Takeda Pharmaceutical Company Limited Cd38-binding fusion protein combination therapy

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5976531A (en) 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
ES2204890T3 (es) 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
HU218140B (hu) 1991-04-25 2000-06-28 Chugai Seiyaku Kabushiki Kaisha Humán interleukin-6-receptorral szembeni átalakított humán antitest
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
AU2071695A (en) 1994-03-17 1995-10-03 Merck Patent Gmbh Anti-EGFR single-chain FVS and anti-EGFR antibodies
EP0706799B1 (en) 1994-09-16 2001-11-14 MERCK PATENT GmbH Immunoconjugates II
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
ATE483733T1 (de) 1995-06-14 2010-10-15 Univ California Hochaffine humane antikörper gegen tumorantigene
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
AU719513B2 (en) 1996-05-04 2000-05-11 Astrazeneca Ab Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6608183B1 (en) 1997-07-14 2003-08-19 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
CZ300762B6 (cs) 1998-10-16 2009-08-05 Biogen Idec Ma Inc. Fúzní proteiny interferonu-beta-1a a jejich použití
EP2264177B1 (en) 1998-12-09 2015-09-30 Phyton Holdings, LLC Glycoproteins having human-type glycosylation
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US7355015B1 (en) 1999-03-12 2008-04-08 Georgetown University School Of Medicine Matriptase, a serine protease and its applications
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
EP1292334A4 (en) 2000-06-22 2003-11-19 Idec Pharma Corp BISPECIFIC FUSION PROTEIN AND METHOD FOR USE TO ENHANCE THE KILLING OF TARGET CELLS BY EFFECTOR CELLS
EP1522590B1 (en) 2000-06-28 2009-08-26 Glycofi, Inc. Methods for producing modified glycoproteins
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
ES2344592T3 (es) 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
FR2823764B1 (fr) 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
ATE433996T1 (de) 2001-07-03 2009-07-15 Genentech Inc Humane dr4-antikörper und deren anwendungen
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
KR100829283B1 (ko) 2002-01-09 2008-05-13 메다렉스, 인코포레이티드 Ｃｄ３０에 대한 인간 모노클로날 항체
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
ATE477276T1 (de) 2002-03-01 2010-08-15 Immunomedics Inc Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7202346B2 (en) 2002-07-03 2007-04-10 Immunogen Inc. Antibodies to non-shed Muc1 and Muc16, and uses thereof
EP1539950A1 (en) 2002-09-09 2005-06-15 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
EP1539960B1 (en) 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
MXPA05008704A (es) 2003-02-18 2005-10-05 Merck Patent Gmbh Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
EP1684869B1 (en) 2003-11-04 2011-07-20 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for b cell-related cancers
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
US8034352B2 (en) 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
WO2005086875A2 (en) 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
SI2287195T1 (sl) 2004-07-01 2019-08-30 Novo Nordisk A/S Pan-kir2dl nk-receptor protitelesa in njihova uporaba pri diagnostiki in terapiji
US7491390B2 (en) 2004-10-15 2009-02-17 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
NZ586780A (en) 2005-03-23 2012-02-24 Genmab As Antibodies against CD38 for treatment of multiple myeloma
EP2799451A1 (en) 2005-05-24 2014-11-05 MorphoSys AG Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
EP1899368A2 (en) 2005-05-26 2008-03-19 Schering Corporation Interferon-igg fusion
EP2476428B1 (en) 2005-06-29 2013-08-21 Yeda Research and Development Co. Ltd. Recombinant interferon alpha 2 (IFN alpha 2) mutants
CA2854576A1 (en) 2005-07-18 2007-01-25 Haichun Huang Human anti-b7rp1 neutralizing antibodies
CA2623236A1 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
US20070190068A1 (en) 2005-10-10 2007-08-16 Richard Hart uPAR-binding molecule-drug conjugates and uses thereof
KR20150139636A (ko) 2005-10-12 2015-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
US8039593B2 (en) 2005-10-31 2011-10-18 Duke University Antibodies and immunotoxins that target human glycoprotein NMB
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
CN101045156B (zh) 2006-03-29 2012-05-02 刘宏利 特异靶向性药物及其用途
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
FR2905375A1 (fr) 2006-08-29 2008-03-07 Biomethodes Sa Variants ameliores de l'interferon alpha humain
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
EP3753576A1 (en) 2006-09-26 2020-12-23 Genmab A/S Combination treatment of cd38-expressing tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
US20110045007A1 (en) 2007-05-31 2011-02-24 Genmab A/S Fusion or linked proteins with extended half life
WO2009017823A2 (en) 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health A fold-back diabody diphtheria toxin immunotoxin and methods of use
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
WO2009073975A1 (en) 2007-12-10 2009-06-18 National Research Council Of Canada Production of recombinant interferon proteins
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US9221914B2 (en) 2007-12-26 2015-12-29 Biotest Ag Agents targeting CD138 and uses thereof
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
WO2010105290A1 (en) 2009-03-16 2010-09-23 Cephalon Australia Pty Ltd Humanised antibodies with anti-tumour activity
RS59769B1 (sr) 2010-06-09 2020-02-28 Genmab As Antitela protiv humanog cd38
US8909257B2 (en) 2010-06-19 2014-12-09 Qualcomm Incorporated Positioning protocol conveyance
KR101912957B1 (ko) * 2010-09-27 2018-10-29 모르포시스 아게 다발성 골수종 및 nhl 치료를 위한 항-cd38 항체 및 레날리도마이드 또는 보르테조밉
MX2013007392A (es) 2010-12-22 2013-11-01 Cephalon Australia Pty Ltd Anticuerpo modificado con vida media mejorada.
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
ES3033729T3 (en) 2011-10-28 2025-08-07 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
ES2694180T3 (es) 2012-01-20 2018-12-18 Vib Vzw Citocinas de haz alfa-helicoidal mutantes dirigidas
IN2014DN08236A (cg-RX-API-DMAC7.html) 2012-03-03 2015-05-15 Immungene Inc
WO2014028502A1 (en) 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
US20150353485A1 (en) 2013-01-25 2015-12-10 Bayer Materialscience Ag Security element having volume hologram and printed feature
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
PT3677591T (pt) * 2013-04-29 2023-02-17 Teva Pharmaceuticals Australia Pty Ltd Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
PE20170908A1 (es) * 2014-10-29 2017-07-12 Teva Pharmaceuticals Australia Pty Ltd VARIANTES DE INTERFERON a2b

Similar Documents

Publication Publication Date Title
JP2017515815A5 (cg-RX-API-DMAC7.html)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2011046732A5 (cg-RX-API-DMAC7.html)
HRP20201656T1 (hr) Neutralizacija inhibitornih putova u limfocitima
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
CL2013003373A1 (es) Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll).
JP2016512551A5 (cg-RX-API-DMAC7.html)
JP2017528462A5 (cg-RX-API-DMAC7.html)
JP2020500538A5 (cg-RX-API-DMAC7.html)
JP2018534933A5 (cg-RX-API-DMAC7.html)
JP2017507954A5 (cg-RX-API-DMAC7.html)
JP2011514150A5 (cg-RX-API-DMAC7.html)
RU2019119862A (ru) Антитела к компоненту комплемента c5
JP2018500014A5 (cg-RX-API-DMAC7.html)
JP2017529838A5 (cg-RX-API-DMAC7.html)
RU2016129517A (ru) Биспецифические антитела к her2 и способы применения
JP2016536361A5 (cg-RX-API-DMAC7.html)
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
FI3699198T3 (fi) Menetelmiä kasvaimen hoitoon bispesifistä CD3XCD20-vasta-ainetta käyttämällä
RU2016100892A (ru) Антитела против tweakr и их применение
RU2020124153A (ru) Гуманизированные антитела к cd19 человека и способы их применения
EP4435009A3 (en) Claudin6 antibodies and methods of treating cancer
NZ710695A (en) Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
JP2014205674A5 (cg-RX-API-DMAC7.html)
RU2017145268A (ru) Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов